{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:05:19Z","timestamp":1783699519180,"version":"3.55.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"medical research council","doi-asserted-by":"publisher","award":["MR\/R014043\/1"],"award-info":[{"award-number":["MR\/R014043\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"cancer research uk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The ReIMAGINE Consortium was conceived to develop risk-stratification models that might incorporate the full range of novel prostate cancer (PCa) diagnostics (both commercial and academic).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>ReIMAGINE Risk is an ethics approved (19\/LO\/1128) multicentre, prospective, observational cohort study which will recruit 1000 treatment-naive men undergoing a multi-parametric MRI (mpMRI) due to an elevated PSA (\u226420ng\/ml) or abnormal prostate examination who subsequently had a suspicious mpMRI (score\u22653, stage \u2264T3bN0M0). Primary outcomes include the detection of \u2265Gleason 7 PCa at baseline and time to clinical progression, metastasis and death. Baseline blood, urine, and biopsy cores for fresh prostate tissue samples (2 targeted and 1 non-targeted) will be biobanked for future analysis. High-resolution scanning of pathology whole-slide imaging and MRI-DICOM images will be collected. Consortium partners will be granted access to data and biobanks to develop and validate biomarkers using correlation to mpMRI, biopsy-based disease status and long-term clinical outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Recruitment began in September 2019(n = 533). A first site opened in September 2019 (n = 296), a second in November 2019 (n = 210) and a third in December 2020 (n = 27). Acceptance to the study has been 65% and a mean of 36.5ml(SD+\/-10.0), 12.9ml(SD+\/-3.7) and 2.8ml(SD+\/-0.7) urine, plasma and serum donated for research, respectively. There are currently 4 academic and 15 commercial partners spanning imaging (~9 radiomics, artificial intelligence\/machine learning), fluidic (~3 blood-based and ~2urine-based) and tissue-based (~1) biomarkers.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The consortium will develop, or adjust, risk models for PCa, and provide a platform for evaluating the role of novel diagnostics in the era of pre-biopsy MRI and targeted biopsy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0259672","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T18:42:50Z","timestamp":1645728170000},"page":"e0259672","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses."],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-3547","authenticated-orcid":true,"given":"Teresa","family":"Marsden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McCartan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-1761","authenticated-orcid":true,"given":"Manuel","family":"Rodriguez-Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-9638","authenticated-orcid":true,"given":"Tom","family":"Syer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Brembilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton","family":"Coolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ReIMAGINE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"pone.0259672.ref001","unstructured":"Excellence NIfHaC. NICE guideline [NG131]: Prostate cancer: diagnosis and management May 201 2019 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng131"},{"key":"pone.0259672.ref002","unstructured":"N. Mottet (Chair) PCV-c, R.C.N. van den Bergh, E. Briers (Patient Representative), M. De Santis, S. Fanti, S. Gillessen, et al. EAU Prostate Cancer Guideline 2019."},{"key":"pone.0259672.ref003","unstructured":"AUA: Pat F. Fulgham MDBR, MD; Jonathan N. Rubenstein, MD; Samir S. Taneja, MD; Peter R. Carroll, MD; Peter A. Pinto, MD; Marc A. Bjurlin, DO, MSc; et al. Standard Operating Procedure for Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. A Collaborative Initiative by the American Urological Association and the Society of Abdominal Radiology Prostate Disease Focus Panel. May 2019 (Revised)."},{"issue":"10071","key":"pone.0259672.ref004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.","volume":"389","author":"HU Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"pone.0259672.ref005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-020-0332-z","article-title":"All change in the prostate cancer diagnostic pathway","volume":"17","author":"DJ Lomas","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0259672.ref006","article-title":"Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence.","author":"A Vickers","year":"2020","journal-title":"Eur Urol"},{"key":"pone.0259672.ref007","unstructured":"Phillips B BC, Sackett D, et al Updated by Howick J. March 2009 [Available from: http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels- evidence-march-2009\/"},{"issue":"5","key":"pone.0259672.ref008","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bju.12223","article-title":"Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system.","volume":"112","author":"L Dickinson","year":"2013","journal-title":"BJU Int"},{"issue":"4","key":"pone.0259672.ref009","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1109\/TBME.2016.2582734","article-title":"Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy","volume":"64","author":"Y Hu","year":"2017","journal-title":"IEEE Trans Biomed Eng"},{"issue":"4","key":"pone.0259672.ref010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","article-title":"Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting","volume":"59","author":"L Dickinson","year":"2011","journal-title":"Eur Urol"},{"issue":"19","key":"pone.0259672.ref011","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"V Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0259672.ref012","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2016.70.9527","article-title":"Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?","volume":"35","author":"AV D\u2019Amico","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0259672.ref013","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2016.09.040","article-title":"Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial","volume":"71","author":"TJ Johnston","year":"2017","journal-title":"Eur Urol"},{"issue":"7637","key":"pone.0259672.ref014","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"M Fraser","year":"2017","journal-title":"Nature"},{"issue":"22","key":"pone.0259672.ref015","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non-Small-Cell Lung Cancer","volume":"376","author":"M Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"issue":"10024","key":"pone.0259672.ref016","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.","volume":"387","author":"ND James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"pone.0259672.ref017","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.","volume":"8","author":"M Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"pone.0259672.ref018","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.18632\/oncotarget.3041","article-title":"Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform.","volume":"6","author":"E Kidess","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"pone.0259672.ref019","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","article-title":"Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.","volume":"12","author":"S Jenkins","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"pone.0259672.ref020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/pcan.2015.40","article-title":"A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result","volume":"18","author":"MJ Donovan","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"13","key":"pone.0259672.ref021","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-14-3334","article-title":"Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer","volume":"21","author":"GH Leyten","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T18:43:15Z","timestamp":1645728195000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259672"}},"subtitle":[],"editor":[{"given":"Henry","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0259672","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}